INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date		10540150
		2005-06-21
First Named Inventor Brian		L. Gibson
Art Unit		1713
Examiner Name	Kelec	zhi Chidi Egwim
Attorney Docket Numb	er	H0003686(2)

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3234197		1966-02-08	Baum	
	2	3322711		1967-05-30	Bush et al.	
	3	3972962		1976-08-03 Williams et al.		
	4	4032473	1977-06-28 Berg et al.		Berg et al.	
	5	4454313		1984-06-12	Okitsu et al.	
	6	4459388	1984-07-10 Hettche et al.			
	7	4681975	1987-07-21 Hasegawa et al.			
	8	4607072		1986-08-19	Su	

#### 

			_			_		
	9	4812504		1989-03-14	Su			
	10	5039740		1991-08-13	Anderson et al.			
	11	5621033		1997-04-15	Lindner			
	12	6060565		2000-05-09	Deckers et al.			
	13	6103791		2000-08-15	Zehner			
	14	6210792	B1	2001-04-03	Soothamraju et al.			
	15	6248813	B1	2001-06-19	Zehner			
	16	6485804		2002-11-26	Nakamachi et al.			
If you wis	h to a	dd additional U.S. Paten			ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, Lin Relevant Passages Figures Appear		es where or Relevant	
	1							

If you wish to add additional U.S. Published Application citation information please click the Add button Add

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

F

A

oplication Number		10540150	
ling Date		2005-06-21	
rst Named Inventor Brian		L. Gibson	
t Unit		1713	
kaminer Name Keled		hi Chidi Egwim	
tomov Docket Number		H0003686(2)	

				FOR	REIGN PAT	ENT DOCUM	IENTS	Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> į	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5		
	1								Г	
If you wis	h to a	dd addition	al Foreign F	atent Docum	ent citation	information p	lease click the Add butt	on Add	_	
				NON-PA	TENT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of to (book, magazine, journal, sortial, symposium, catalog, etc), date, pages(s), volume-issue number(t publisher, city and/or country where published.						Ţδ			
	1	Edenbaum	n, J., Ed., Pla	stic Additives a	nd Modifiers	Handbook, Va	n Nostrand Reinhold, New	York 1992, Chapter 3		
If you wis	h to a	dd addition	al non-pate	nt literature do	cument cit	ation informa	tion please click the Add	button Add		
					EXAMINE	R SIGNATUR	RE			
Examiner	Signa	ture					Date Considered			
*EXAMIN	ER: Ir	itial if refer					formance with MPEP 60 with next communication			

1 See Kint Code of USPTO Patent Documents at year USPTO\_GOV or MFEP 601.04. 2 Enter office that issued the document, by the bo-witter code (WIPO Standard ST.3). 2 For Japanese patent comments, be included not see year of the Emporer many procedure is enter insured for the patent counter.

\*\*Gird of Gourment by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Emplin hanguages transitation is attacked.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10540150		
Filing Date		2005-06-21		
First Named Inventor Brian		L. Gibson		
Art Unit		1713		
Examiner Name Keled		hi Chidi Egwim		
Attorney Docket Number		H0003686(2)		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.90 to make th	ie appropriate s	election(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/jimmiejohnson/	Date (YYYY-MM-DD)	2007-06-14
Name/Print	Jimmie D. Johnson	Registration Number	52 485

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.